Preview

Современная парадигма послеоперационного ведения больных c дифференцированным раком щитовидной железы

https://doi.org/10.14341/ket2011738-21

Полный текст:

Аннотация

Под парадигмами я подразумеваю признанные всеми научные достижения, которые в течение определенного времени дают модель постановки проблем и их решений научному сообществу. Томас Кун Рак щитовидной железы (РЩЖ) является наиболее часто встречающейся злокачественной опухолью эндокринной системы [1]. Стандартизованный показатель заболеваемости РЩЖ в различных странах мира варьирует от 0,8 до 9,4 случая на 100 000 населения в год среди женщин и от 0,6 до 2,6 случая на 100 000 населения в год среди мужчин [6]. В России заболеваемость РЩЖ достигает 8000 новых случаев в год [2].

Об авторах

N P Makolina

доктор мед. наук, главный научный сотрудник ФГБУ Эндокринологический научный центр


N M Platonova

доктор мед. наук, главный научный сотрудник ФГБУ Эндокринологический научный центр


Список литературы

1. Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак щитовидной железы // М.: ГЭОТАР-Медиа, 2009. С. 29–30.

2. Статистика злокачественных новообразований в России и странах СНГ в 2004 г.// Вестник РОНЦ им. Н.Н. Блохина РАМН, 2006. Т. 17. №3. С. 47.

3. Дедов И.И., Мельниченко Г.А., Трошина Е.А. и др. Спорные вопросы тактики лечения дифференцированного рака щитовидной железы // Пробл. эндокринол., 2008. Т.54. №2. С. 14–22.

4. Национальные клинические рекомендации по диагностике и лечению дифференцированного рака щитовидной железы // Эндокринная хирургия. 2008. №1(2). С. 3–5.

5. Гарбузов П.И., Дроздовский Б.Я., Родичев А.А. и др. Радиойодтерапия рака щитовидной железы// Практическая онкология, 2007. Т8. №1. С. 42–45.

6. Pacini F., Schlumberger M., Dralle H. et al. The European thyroid cancer taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium // Europ. J. Endocrinol., 2006. V. 154. P. 787–803.

7. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002 // JAMA. 2006. V. 295(18). P. 2179–2182.

8. Barczynski M., Barczynski M.L. Current management of thyroid cancer – a change of therapeutic strategy over the last 20 years // Przegl. Lek. 2000. V. 57(5). P. 105–107.

9. Schlumberger M.J., Torlantano M. Papillary and follicular thyroid carcinoma // Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 2000. V. 14(4). P. 601–613.

10. Salvatori M., Rufini V., Garganese M.C. et al. Radioiodine therapy in differentiated thyroid carcinoma // Rays. 2000. V. 25(2). P. 221–238.

11. Tuttle R.M., Ball D.W., Byrd D. et al. Thyroid Carcinoma // J. Natl. Compr. Canc. Netw. 2010. V. 8. P. 1228–1274.

12. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer // Am. J. Med. 1994. V. 97. Р. 418–428.

13. DeGroot L.J., Kaplan E.L., McCormick M. Natural history, treatment, and course of papillary thyroid carcinoma // J. Clin. Endocrinol. Metab. 1992. V. 71(2). P. 414–424.

14. Samaan N.A., Schultz P.N., Hickey R.C. et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients // J. Clin. Endocrinol. Metab. 1992. V. 75(3). Р. 714–720.

15. Mazzaferri E.L., Jhiang S.M. Differentiated thyroid cancer long-term impact of initial therapy // Trans. Am. Clin. Climatol. Assoc. 1995. V. 106. P. 151–168

16. Taylor T., Specker B., Robbins J. et al. Outcome after treatment of high-risk papillary and non-Hьrthle-cell follicular thyroid carcinoma // Ann. Intern. Med. 1998. V. 15(129). Р. 622–627.

17. Sawka A.M., Brierley J.D., Tsang R.W. et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer // Endocrinol. Metab. Clin. North. Am. 2008. V. 37(2). P. 457–480.

18. Hundahl S.A., Fleming I.D., Fremgen A.M. et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 // Cancer. 1998. V. 15. N. 83(12). P. 2638–2648.

19. Sanders L.E., Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment // Arch. Surg. 1998. V. 133(4). P. 419–425.

20. Kim S., Wei J.P., Braveman J.M., Brams D.M. Predicting outcome and directing therapy for papillary thyroid carcinoma // Arch. Surg. 2004. V. 139(4). P. 393–394.

21. Lundgren C.I., Hall P., Dickman P.W., Zedenius J. Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer // Br. J. Surg. 2007. V. 94(5). P. 571–577.

22. Hay I.D., Thompson G.B., Grant C.S. et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients // World. J. Surg. 2002. V. 26(8). P. 879–885.

23. DeGroot L.J., Kaplan E.L., McCormick M., Straus F.H. Natural history, treatment, and course of papillary thyroid carcinoma // J. Clin. Endocrinol. Metab. 1990. V. 71(2). P. 414–424.

24. Mazzaferri E.L. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma // Thyroid. 1997. V. 7(2). P. 265–271.

25. Jung T.S., Kim T.Y., Kim K.W. et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma // Endocr. J. 2007. V. 54(2). P. 265–274.

26. Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer // Thyroid. 2009. V. 19(11). P. 1167–1214.

27. Hay I.D., Hutchinson M.E., Gonzalez-Losada T. et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period // Surgery. 2008. V. 144(6). P. 980–987.

28. Ross D.S., Litofsky D., Cooper D.S. et al. Recurrence after treatment of micropapillary thyroid cancer // Thyroid. 2009. V. 19(10). P. 1043–1048.

29. Rosario P.W., Reis J.S., Barroso A.L. et al. Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake // Nucl. Med. Commun. 2004. V. 25(11). P. 1077–1081.

30. Johansen K., Woodhouse N.J., Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer // J. Nucl. Med. 1991. V. 32(2). P. 252–254.

31. Doi S.A., Woodhouse N.J, Thalib L. et al. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta- analysis revisited // Clin. Med. Res. 2007. V. 5(2). P. 87–90.

32. Hackshaw A., Harmer C., Mallick U. et al. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systemat- ic review // J. Clin. Endocrinol. Metab. 2007. V. 92(1). P. 28–38.

33. Maenpaa H.O., Heikkonen J., Vaalavirta L. et al. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study // PLoS One. 2008. V. 3(4). P. 1885.

34. Pacini F., Schlumberger M., Harmer C. et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report // Eur. J. Endocrinol. 2005. V. 153(5). P. 651–659.

35. al-Nahhas A.M. Ablation in differentiated thyroid carcinoma: Haw much surgery? How much iodine? // Nucl. Med. Commun. 1999. V. 20(7). P. 595–597.

36. Menzel C., Grunwald F., Schomburg A. et al. “High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma // J. Nucl. Med. 1996. V. 37(9). P. 1496–1503.

37. De Keizer B., Koppeschaar H.P., Zelissen P.M. et al. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin // Eur. J. Nucl. Med. 2001. V. 28(2). P.198–202.

38. Verkooijen R.B., Stokkel M.P., Smit J.W. Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy // Eur. J. Nucl. Med. Mol. Imaging. 2004. V. 31(4). P. 499–506.

39. Luster M., Lippi F., Pacini F. et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review // Endocr. Relat. Cancer. 2005. V. 12(1). P. 49–64.

40. Mazzaferri E.L., Kloos R.T. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions // Thyroid. 2000. V. 10(9). P. 767–778.

41. Elisei R., Schlumberger M., Driedger A. et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal // J. Clin. Endocrinol. Metab. 2009. V. 94(11). P. 4171–4179.

42. Bombardieri E., Seregni E., Villano C. et al. Recombinant human thyrotropin (rhTSH) in the follow-up and treatment of patients with thyroid cancer // Tumori. 2003. V. 89(5). P. 533–536.

43. Emerson C.H., Torres M.S. Recombinant human thyroid-stimulating hormone: pharmacology, clinical applications and potential use // BioDrugs. 2003. V. 17(1). P. 19–38.

44. Hilts S.V., Hellman D., Anderson J. et al. Serial TSH determina- tions after T3 withdrawal or thyroidectomy in the therapy of thy- roid carcinomas // J. Nucl. Med. 1979. V. 20. P. 928–932.

45. Mazzaferri E.L. Radioiodine and other treatments and outcomes. In: Braverman L.E., Utiger R.D., Ingbar S.H., Werner S.C. Werner and Ingbar’s the thyroid: a fundamental and clinical textbook // 8th ed. Philadelphia: Lippincott-Williams, Wilkins. 2000. P. 904–929.

46. Meier C.A., Braverman L.E., Ebner S. et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study) // J. Clin. Endocrinol. Metab. 1994. V. 78. P. 188–196.

47. Tamai H., Suemastu H., Kurokawa N. et al. Alterations in circulating thyroid hormones and thyrotropin after complete thyroidectomy // J. Clin. Endocrinol. Metab. 1979. V. 48. P. 54–58.

48. Klain M.R.M., Leboulleux S., Baudin E., Schlumberger M. Radioiodine therapy for papillary and follicular thyroid carcinoma // Eur. J. Nucl. Med. Mol. Imaging. 2002; 29 (suppl 2): S. 479–S85.

49. Singer P.A., Cooper D.S., Daniels G.H. et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer // Arch. Intern. Med. 1996. V. 156. P. 2165–2172.

50. Meier D.A., Brill D.R., Becker D.V. et al. Procedure guideline for therapy of thyroid disease with 131 iodine // J. Med. Nucl. 2002. V. 43. P.856–861.

51. Liel Y. Preparation for radioactive iodine administration in differentiated thyroid cancer patients // Clin. Endocrinol. (Oxf). 2002. V. 57. P. 523–527.

52. Serhal D.I., Nasrallah M.P., Arafah B.M. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer // J. Clin. Endocrinol. Metab. 2004. V. 89(7). P. 3285–3289.

53. Sanchez R., Espinoza-de-los-Monteros A.L., Mendoza V. Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma // Arch. Med. Res. 2002. V. 33. P. 478–481.

54. Grigsby P.W., Siegel B.A., Bekker S. et al. Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1–3 weeks of thyroxine discontinuation // J. Nucl. Med. 2004. V. 45(4). P. 567–570.

55. Leboeuf R., Perron P., Carpentier A.C. et al. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial // Clinical Endocrinology. 2007. V. 67(6). P. 839–844.

56. Lee J., Yun M.J., Nam K.H. et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma // Thyroid. 2010. V. 20(2). P. 173–179.

57. Taпeb D., Sebag F., Cherenko M. et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study // Clin. Endocrinol. (Oxf). 2009. V. 71(1). P. 115–123.

58. Solans R., Bosch J.A., Galofre P. et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy // J. Nucl Med. 2001. V. 42(5). P. 738–743.

59. Sherman S.I., Brierley J.D., Sperling M. et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group // Cancer. 1998. V. 83. P. 1012–1021.

60. Brierley J.D., Panzarella T., Tsang R.W. et al. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example // Cancer. 1997. V 79. P. 2414–2423.

61. Loh K.C., Greenspan F.S., Gee L. et al. Pathological tumor-node metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients // J. Clin. Endocrinol. Metab. 1997. V. 82. P. 3553–3562.

62. Wittekind C., Compton C.C., Greene F.L. et al. TNM residual tumor classification revisited // Cancer. 2002. V. 94. P. 2511–2516.

63. Hay I.D., Bergstralh E.J., Goellner J.R. et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 // Surgery. 1993. V. 114. P. 1050–1057.

64. Byar D.P., Green S.B., Dor P. et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group // Eur. J. Cancer. 1979. V. 15. P. 1033–1041.

65. Shaha A.R., Loree T.R., Shah J.P. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid // Surgery. 1995. V. 118. P. 1131–1136.

66. Shaha A.R. Controversis in the management of thyroid nodule // Laryngoscope. 2000. V. 110. P. 183–193.

67. Schlumberger M., Berg G., Cohen O. et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective // Eur. J. Endocrinol. 2004. V. 150. P. 105–112.

68. Rouxel A., Hejblum G., Bernier M.O. et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas // J. Clin. Endocrinol. Metab. 2004. V. 89. P. 5362–5368.

69. Wenig B.M., Thompson L.D., Adair C.F. et al. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases // Cancer. 1998. V. 82. P. 740–753.

70. Akslen L.A., Livolsi V.A. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma // Cancer. 2000. V. 88. P. 1902–1908.

71. Tuttle R.M., Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm // Endocrinol. Metab. Clin. North. Am. 2008. V. 37. P. 419–435.

72. Esnajla N.F., Cantor S.B., Sherman S.I. et al. Optimal treatment strategy in patients with papillary thyroid cancer: A decision analysis // J. Surgery. 2001. V. 130. P. 921–930.

73. Cooper D.S., Specker B., Ho M. et.al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry // Thyroid. 1998. V. 8. P. 737–744.

74. Vera P., Kuhn-Lansoy C., Edet-Sanson A. et al. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? // Thyroid. 2010. V. 20(1). P. 15–23.

75. Haugen B.R., Pacini F., Reiners C. et al. A comparison of recombi- nant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer // J. Clin. Endocrinol. Metab. 1999. V. 84. P. 3877–3885.

76. Robbins R.J., Tuttle R.M., Sharaf R.N. et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma // J. Clin. Endocrinol. Metab. 2001. V. 86. P. 619–625.

77. Pacini F., Molinaro E., Lippi F. et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma // J. Clin. Endocrinol. Metab. 2001. V. 86. P. 5686–5690.

78. Haugen B.R., Ridgway E.C., McLaughlin B.A. et al. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin // Thyroid. 2002. V. 12. P. 37–43.

79. Pacini F., Capezzone M., Elisei R. et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment // J. Clin. Endocrinol. Metab. 2002. V. 87. P. 1499–1501.

80. Robbins R.J., Chon J.T., Fleisher M. et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? // J. Clin. Endocrinol. Metab. 2002. V. 87. P. 3242–3247.

81. Wartofsky L. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin // Thyroid. 2002. V.12. P. 583–590.

82. Mazzaferri E.L., Robbins R.J., Spencer C.A. et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma // J. Clin. Endocrinol. Metab. 2003. V. 88. P. 1433–1441.

83. Pacini F., Molinaro E., Castagna M.G. et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma // J. Clin. Endocrinol. Metab. 2003. V. 8. P. 3668–3673.

84. Kloos R.T., Mazzaferri E.L. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later // J. Clin. Endocrinol. Metab. 2005. V. 90. P. 5047–5057.

85. Mazzaferri E.L., Robbins R.J., Braverman L.E. et al. Author’s response: a consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma // J. Clin. Endocrinol. Metab. 2003. V. 88. P. 4508–4509.

86. Smallridge R.C., Meek S.E., Morgan M.A. et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to rhTSH-stimulated thyroglobulin in follow-up of thyroid cancer patients // J. Clin. Endocrinol. Metab. 2007. V. 92(1). P. 82–87.

87. Ericsson U.B., Christensen S.B., Thorell J.I. A high prevalence of thyroglobulin autoantibodies in adults with and without thyroid disease as measured with a sensitive solid-phase immunosorbent radioassay // Clin. Immunol. Immunopathol. 1985. V. 37. P. 154–162.

88. Kumar A., Shah Dh., Shrihari U. et al. Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma // Thyroid. 1994. V. 4. P. 199–202.

89. Spencer C.A., Takeuchi M., Kazarosyan M. et al. Serum thyroglobulin futoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma // J. Clin. Endocrinol. Metab. 1998. V. 83(4). P. 1121–1127.

90. Pacini F., Fugazzola L., Lippi F. et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer // J. Clin. Endocrinol. Metab. 1992. V. 74(6). P. 1401–1404.

91. Gharib H., Papini E., Paschke R. et al. AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules // Endocr. Pract. 2010. V. 16(1). P. 1–43.

92. Boi F., Baghino G., Atzeni F. et al. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti- Tg antibodies // J. Clin. Endocrinol. Metab. 2006. V. 91(4). P. 1364–1369.

93. Whitley R.J., Ain K.B. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma // Clin. Lab. Med. 2004. V.24.P. 29–47.

94. Milas M., Barbosa G.F., Mitchell J. et al. Effectiveness of peripheral. thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer // Ann. Surg. Oncol. 2009. V. 16(2). P. 473–480.

95. Savagner F., Rodien P., Reynier P. et al. Analysis of Tg Transcripts by Real-Time RT-PCR in the Blood of Thyroid Cancer Patients // J. Clin. Endocrinol. Metab. 2002. V. 87(2). P. 635–639.

96. Ditkoff B.A., Marvin M.R., Yemul S. et al. Detection of circulating thyroid cells in peripheral blood // Surgery. 1996. V. 120. P. 959–964.

97. Wingo S.T., Ringel M.D., Anderson J.S. et al. Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects // Clin. Chem. 1999. V. 45. P. 785–789.

98. Demers L.M., Spencer C.A. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease // Clin. Endocrinol (Oxf). 2003. V. 58(2). P. 138–140.

99. Links T.P., van Tol K.M., Jager P.L. et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis // Endocr. Relat. Cancer. 2005. V. 12(2). P. 273–280.

100. Mazzaferri E.L., Kloos R.T. Is Diagnostic Iodine-131 Scanning with Recombinant Human TSH Useful in the Follow-Up of Differentiated Thyroid Cancer after Thyroid Ablation? // J. Clin. Endocrinol. Metab. 2002. V. 87(4). P.1490–1498.

101. Tuttle R.M. Risk-adapted management of thyroid cancer // Endocr. Pract. 2008. V. 14(6). P. 764–774.

102. McDougall I.R. 131I treatment of 131I negative whole-body scan, and positive thyroglobulin in differentiated thyriod carcinoma: what is being treated? // Thyriod. 1997. V. 7(4). P. 669–672.

103. Crippa F., Alessi A., Gerali A. et al. FDG-PET in thyroid cancer // Tumori. 2003. V. 89(5). P. 540–543.

104. Nanni C., Rubello D., Fanti S. et al. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer // Biomed. Pharmacother. 2006. V. 60(8). P. 409–413.

105. Pacini F., Castagna M. G., Brilli L. et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2010. V. 21 (suppl 5). P. 214–219.

106. Kloos R.T. Thyroid Cancer Recurrence in Patients Clinically Free of Disease with Undetectable or Very Low Serum Thyroglobulin Values // J. Clin. Endocrinol. Metab. 2010. V. 95(12). P. 5241–5248.

107. Cailleux A.F., Baudin E., Travagli J.P. et al. Is diagnostic iodinescanning useful after total thyroid ablation for differentiated thyroid cancer? // J. Clin. Endocrinol. Metab. 2000. V. 85. P. 175–178.

108. David A., Blotta A., Bondanelli M. et al. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone // J. Nucl. Med. 2001. V. 42. P. 1470–1475.

109. Vitale G., Lupoli G.A., Ciccarelli et al. A The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre // Clin. Endocrinol. (Oxf). 2002. V. 56. P. 247–252.

110. McGriff N.J., Csako G., Gourgiotis L. et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer // Ann. Med. 2002. V. 34. P. 554–564.

111. Pujol P., Daures J.P., Nsakala N. et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer // J. Clin. Endocrinol. Metab. 1996. V. 81. P. 4318–4323.

112. Jonklaas J., Sarlis N.J., Litofsky D. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy // Thyroid. 2006. V. 16. P. 1229–1242.

113. Sawin C.T., Geller A., Wolf P.A. et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons // N. Engl. J. Med. 1994. V. 33. P. 1249–1252.

114. Toft A.D. Clinical practice. Subclinical hyperthyroidism // N. Engl. J. Med. 2001. V. 345. P. 512–516.

115. Ozata M., Suzuki S., Miyamoto T. et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer // J. Clin. Endocrinol. Metab. 1994. V. 79. P. 98–105.


Для цитирования:


Makolina N.P., Platonova N.M. Современная парадигма послеоперационного ведения больных c дифференцированным раком щитовидной железы. Клиническая и экспериментальная тиреоидология. 2011;7(3):8-21. https://doi.org/10.14341/ket2011738-21

For citation:


., . Modern paradigm of postoperative management in patients with well-differentiated thyroid cancer. Clinical and experimental thyroidology. 2011;7(3):8-21. (In Russ.) https://doi.org/10.14341/ket2011738-21

Просмотров: 56


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-5472 (Print)
ISSN 2310-3787 (Online)